Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). 2006

David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
Divisions of Oncology and Hematology, Children's Hospital of Philadelphia, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA. teacheyd@email.chop.edu

Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of abnormal lymphocyte survival caused by defective Fas-mediated apoptosis, leading to lymphadenopathy, hepatosplenomegaly, and an increased number of double-negative T cells (DNTs). Treatment options for patients with ALPS are limited. Rapamycin has been shown to induce apoptosis in normal and malignant lymphocytes. Since ALPS is caused by defective lymphocyte apoptosis, we hypothesized that rapamycin would be effective in treating ALPS. We tested this hypothesis using rapamycin in murine models of ALPS. We followed treatment response with serial assessment of DNTs by flow cytometry in blood and lymphoid tissue, by serial monitoring of lymph node and spleen size with ultrasonography, and by enzyme-linked immunosorbent assay (ELISA) for anti-double-stranded DNA (dsDNA) antibodies. Three-dimensional ultrasound measurements in the mice correlated to actual tissue measurements at death (r = .9648). We found a dramatic and statistically significant decrease in DNTs, lymphadenopathy, splenomegaly, and autoantibodies after only 4 weeks when comparing rapamycin-treated mice with controls. Rapamycin induced apoptosis through the intrinsic mitochondrial pathway. We compared rapamycin to mycophenolate mofetil, a second-line agent used to treat ALPS, and found rapamycin's control of lymphoproliferation was superior. We conclude that rapamycin is an effective treatment for murine ALPS and should be explored as treatment for affected humans.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008221 Lymphoid Tissue Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS. Lymphatic Tissue,Lymphatic Tissues,Lymphoid Tissues,Tissue, Lymphatic,Tissue, Lymphoid,Tissues, Lymphatic,Tissues, Lymphoid
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D008817 Mice, Mutant Strains Mice bearing mutant genes which are phenotypically expressed in the animals. Mouse, Mutant Strain,Mutant Mouse Strain,Mutant Strain of Mouse,Mutant Strains of Mice,Mice Mutant Strain,Mice Mutant Strains,Mouse Mutant Strain,Mouse Mutant Strains,Mouse Strain, Mutant,Mouse Strains, Mutant,Mutant Mouse Strains,Mutant Strain Mouse,Mutant Strains Mice,Strain Mouse, Mutant,Strain, Mutant Mouse,Strains Mice, Mutant,Strains, Mutant Mouse
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D011494 Protein Kinases A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein. Protein Kinase,Kinase, Protein,Kinases, Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune

Related Publications

David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
January 2003, Current pharmaceutical design,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
January 2000, Ryoikibetsu shokogun shirizu,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
February 2012, Pediatric blood & cancer,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
March 2023, HemaSphere,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
February 2016, Clinical reviews in allergy & immunology,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
January 2019, Frontiers in immunology,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
October 2017, Ocular immunology and inflammation,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
November 2021, Expert review of clinical immunology,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
January 2019, Frontiers in immunology,
David T Teachey, and Dana A Obzut, and Kelly Axsom, and John K Choi, and Kelly C Goldsmith, and Junior Hall, and Jessica Hulitt, and Catherine S Manno, and John M Maris, and Nicholas Rhodin, and Kathleen E Sullivan, and Valerie I Brown, and Stephan A Grupp
August 2000, Clinical and experimental immunology,
Copied contents to your clipboard!